Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression
Wei-Qiang Yang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Wnt Signaling and Drug Resistance in Cancer
Zheng Zhong et al.
MOLECULAR PHARMACOLOGY (2020)
DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4
Janani Panneerselvam et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Discovery of a selective inhibitor of doublecortin like kinase 1
Fleur M. Ferguson et al.
NATURE CHEMICAL BIOLOGY (2020)
DCLK1 inhibition attenuates tumorigenesis and improves chemosensitivity in esophageal squamous cell carcinoma by inhibiting β-catenin/c-Myc signaling
Lianqun Zhang et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2020)
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
Leilei Wu et al.
FRONTIERS IN ONCOLOGY (2020)
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
J. Gao et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice
Prasad Dandawate et al.
GASTROENTEROLOGY (2019)
Cancer stem cells (CSCs) in cancer progression and therapy
Masoud Najafi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
Zheng-Hai Tang et al.
CANCER LETTERS (2018)
Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer
Yang Ge et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
Tony S. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer
Hiroyuki Tao et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening
Julia Joung et al.
NATURE PROTOCOLS (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Roel Nusse et al.
CELL (2017)
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
Puyu Shi et al.
CANCER LETTERS (2016)
Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis
C. Benedikt Westphalen et al.
CELL STEM CELL (2016)
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC
Melissa Bersanelli et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors
Shuhang Wang et al.
FRONTIERS OF MEDICINE (2016)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition
Simona Coco et al.
TARGETED ONCOLOGY (2015)
XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism
Sripathi M. Sureban et al.
CANCER LETTERS (2014)
Long-lived intestinal tuft cells serve as colon cancer-initiating cells
C. Benedikt Westphalen et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1
Nathaniel Weygant et al.
MOLECULAR CANCER (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
Kai Wang et al.
NATURE GENETICS (2014)
Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Elza C. de Bruin et al.
CANCER DISCOVERY (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Dclk1 distinguishes between tumor and normal stem cells in the intestine
Yuki Nakanishi et al.
NATURE GENETICS (2013)
Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer
Jiujie Cui et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Kadoaki Ohashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
EGFR Mutations and Lung Cancer
Gilda da Cunha Santos et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L. Sos et al.
CANCER RESEARCH (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors
Kwok-Kin Wong
LUNG CANCER (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
QB She et al.
CANCER CELL (2005)
Share Paper
